Celldex Therapeutics
CLDX
CLDX
167 hedge funds and large institutions have $2.15B invested in Celldex Therapeutics in 2022 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 50 increasing their positions, 57 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
6% more funds holding
Funds holding: 158 → 167 (+9)
1.57% less ownership
Funds ownership: 104.89% → 103.31% (-1.6%)
12% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 57
Holders
167
Holding in Top 10
6
Calls
$35.1M
Puts
$17.1M
Top Buyers
| 1 | +$69.8M | |
| 2 | +$16.5M | |
| 3 | +$12.5M | |
| 4 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
+$12M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$4.5M |
Top Sellers
| 1 | -$39.2M | |
| 2 | -$33M | |
| 3 | -$14.7M | |
| 4 |
Goldman Sachs
New York
|
-$9.58M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$6.78M |